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Abstract
Background: The 2009 pandemic influenza was milder than expected. Based on the apparent lack of pre-existing
cross-protective antibodies to the A (H1N1)pdm09 strain, it was hypothesized that pre-existing CD4+ T cellular
immunity provided the crucial immunity that led to an attenuation of disease severity. We carried out a pilot scale
study by conducting in silico and in vitro T cellular assays in healthy population, to evaluate the pre-existing
immunity to A (H1N1)pdm09 strain.
Methods: Large-scale epitope prediction analysis was done by examining the NCBI available (H1N1) HA proteins.
NetMHCIIpan, an eptiope prediction tool was used to identify the putative and shared CD4+ T cell epitopes
between seasonal H1N1 and A (H1N1)pdm09 strains. To identify the immunogenicity of these putative epitopes,
human IFN-γ-ELISPOT assays were conducted using the peripheral blood mononuclear cells from fourteen healthy
human donors. All donors were screened for the HLA-DRB1 alleles.
Results: Epitope-specific CD4+ T cellular memory responses (IFN-γ) were generated to highly conserved HA
epitopes from majority of the donors (93%). Higher magnitude of the CD4+ T cell responses was observed in the
older adults. The study identified two HA2 immunodominant CD4+ T cell epitopes, of which one was found to be
novel.
Conclusions: The current study provides a compelling evidence of HA epitope specific CD4+ T cellular memory
towards A (H1N1)pdm09 strain. These well-characterized epitopes could recruit alternative immunological pathways
to overcome the challenge of annual seasonal flu vaccine escape.
Keywords: Influenza A/H1N1 viruses, Hemagglutinin, CD4+ T cell epitope, Immunodominant epitope, Novel
conserved HA epitope
Background
A pandemic influenza A H1N1 virus, A (H1N1)pdm09,
emerged in April 2009 with a unique combination of
genes that have not been reported previously in swine
or humans [1]. A large proportion of the human popula-
tion displayed a lack of cross-reactive neutralizing anti-
bodies to A (H1N1)pdm09 virus, a situation accepted to
be due to the novel antigenicity of the virus [2]. This
immunologically naïve context of the human population
was responsible for the rapid global spread of the virus
leading the World Health Organization to declare a
pandemic on June 11, 2009. Despite being highly patho-
genic in laboratory animals, A (H1N1)pdm09 virus un-
expectedly turned out to be a milder strain in humans,
and was also found to be self-limiting in disease spread
in the majority of documented human cases [3,4]. A
possible explanation for this unanticipated scenario is
the presence of pre-existing T-cellular responses to-
wards the highly conserved protein regions shared by
seasonal influenza A H1N1 and A (H1N1)pdm09 that
would result in limited virus spread, although not
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limited establishment of infection [5,6]. The importance
of CD4+ T cell responses in influenza infection is well
documented. CD4+ T cell responses provide cross-
reactive immunity to different influenza strains even in
the absence of significant antibody titers; they have a
crucial role in maintaining the effector CD8+ T cell
functions during a primary response and they are in-
volved in compensating for CD8+ T cells diminished in
cytolytic activity, particularly in older adults [7,8]. Given
the importance of CD4+ T helper cells in shaping cross-
Table 1 Predicted CD4+ HA T cell epitopes of A(H1N1)pdm09 viruses and their conservancy in seasonal H1N1
(1977–2009) viruses
Predicted CD4+ T- cell
epitopes (15 a. a) (epitope
position)
% of predicted epitope
conservancy in seasonal H1N1
(1977–2009) HA proteins
% seasonal H1N1(1977–2009)
isolates with each of the
conserved epitope
% A(H1N1)pdm09 (2009–2010)
isolates with each of the
conserved epitope
VLEKNVTVTHSVNLL 100 100 99
(HA1 19–33)
EELREQLSSVSSFER 100 100 99
(HA1 99–113)
QLSSVSSFERFEIFP 100 100 99
(104–119)
ATGLRNIPSIQSRGL 93 97 98
(HA1 315–329)
GLRNIPSIQSRGLFG 100 97 100
(HA1 317–331)
RNIPSIQSRGLFGAI 100 97 98
(HA1 319–333)
QSRGLFGAIAGFIEG 100 100 100
(HA1 325–339)
NKVNSVIEKMNTQFT 100 96 99
(HA2 377–391)
VIEKMNTQFTAVGKE 100 96 99
(HA2 382–396)
DGFLDIWTYNAELLV 100 96 99
(HA2 413–427)
WTYNAELLVLLENER 100 99 100
(HA2 419–433)
TYNAELLVLLENERT 100 99 100
(HA2 420–434)
YNAELLVLLENERTL 100 100 100
(HA2 421–435)
LVLLENERTLDYHDS 100 98 100
(HA2 426–440)
IYQILAIYSTVASSL 93 100 100
(HA2 510–524)
YQILAIYSTVASSLV 100 100 100
(HA2 511–525)
STVASSLVLLVSLGA 93 100 98
(HA2 518–532)
GAISFWMCSNGSLQC 100 98 99
(HA2 531–545)
Bold faced epitopes were used in in vitro assays.
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Predicted DRB1 alleles Predicted alleles of other DR haplotypes (DRB3, 4 and 5)
Alleles predicted to




Alleles predicted to bind
weakly with each epitope
based on threshold
binding affinity, >50 nM to
<500 nM.
Alleles predicted to bind
strongly with each epitope
based on threshold binding
affinity, <50 nM.
Alleles predicted to bind
weakly with each epitope
based on threshold binding





HA1 99-113 - DRB1*0101,DRB1*0701, DRB5*0202 DRB3*0201,DRB4*0101
DRB1* 1001 DRB5*0101
HA1 104-119 - DRB1*0701,DRB1*1201 - DRB5*0101,DRB5*0202









HA1 319-333 DRB1*1201 DRB1*0701,DRB1*0801, DRB5*0202 DRB3*0201,DRB4*0101
DRB1*1301,DRB1*1501
HA1 325-339 DRB1*0101 DRB1*0701,DRB1*1201, - DRB5*0101,DRB5*0202
DRB1*1501
HA2 377-391 - DRB1*0801,DRB1*1201, - DRB5*0202
DRB1*1301
HA2 382-396 - DRB1*0101,DRB1*0401, DRB5*0202 DRB3*0201
DRB1*0801,DRB1*1201




HA2 419-433 - DRB1*0101 - DRB3*0301,DRB5*0202
HA2 420-434 - DRB1*0101,DRB1*0401, - DRB3*0201,DRB4*0101
DRB1*0404,DRB1*1201 DRB5*0202




HA2 426-440 DRB1*0101 DRB1*0301,DRB1*0401, - DRB3*0201,DRB3*0301
DRB1*1001,DRB1*1201, DRB4*0101,DRB5*0202
DRB1*1301
HA2 510-524 DRB1*0101,DRB1*0404, DRB1*0401,DRB1*0901, DRB5*0202 DRB3*0201,DRB3*0301
DRB1*0701,DRB1*0801, DRB1*1101,DRB1*1301 DRB4*0101,DRB5*0101
DRB1*1001,DRB1*1201
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reactive B-cell and T-cell immune responses and the
conservation and function of the hemagglutinin (HA)
protein in the influenza viral life cycle, we investigated
the immunogenic potential of conserved HA CD4+ T
cell epitopes, shared between seasonal H1N1 and A
(H1N1)pdm09. Our findings lead to the conclusion that
recall responses from CD4+ memory T cells generated
by previous exposure to seasonal H1N1 viruses and also
identifies a highly conserved, novel immunodominant
CD4+ T cell epitope that would be a promising target
for universal epitope-based influenza vaccines.
Methods
Hemagglutinin (HA) protein sequences
Accessing the National Center for Biotechnology Informa-
tion (NCBI) yielded 924 and 890 HA protein sequences of
seasonal H1N1 (1977–2009), and A (H1N1)pdm09 (2009–
2010) respectively. BioEdit software program was used for
sequence analysis.
Epitope prediction, selection of optimal epitopes and
epitope synthesis
The NetMHCIIpan epitope prediction program was uti-
lized to identify the optimal CD4+ T cell epitopes
(length 15 a.a.) from the HA of A(H1N1)pdm09 based
on the binding affinities of epitope-MHC II allele com-
plex [9]. The following criteria were applied to select the
predicted epitopes from the A (H1N1)pdm09 strain
(Table 1): greater than 90% of predicted epitope conser-
vancy in seasonal H1N1(1977–2009) HA proteins, greater
than >90% seasonal H1N1(1977–2009) isolates with each
of the conserved epitope and greater than >90% A(H1N1)
pdm09 (2009–2010) isolates with each of the conserved
epitope [10]. Human leukocyte antigen (HLA)-DRB1 al-
leles were selected because of their wide coverage in the
human population (~99%) [11,12]. A total of 18 CD4+ T
cell epitopes of HA met the epitope selection criteria, of
which 13 epitopes were selected for the experimental ana-
lysis randomly (bolded in Table 2). These 13 conserved
epitopes were synthesized by Proimmune Inc (Florida,
USA), at the recommended purity for ELISPOT assays.
Recruitment of human donors and blood collection
This study was performed at York University, Toronto,
Canada with appropriate approvals from the Institutional
Review Board and Institutional Biosafety Committee dur-
ing January 2010 to December 2010. Fourteen healthy hu-
man donors with an age range of 22 to 66 years were
recruited randomly and all donors were provided with in-
formed consent forms. In order to gather information on
previous influenza exposure history (immunizations and/
or influenza-like illness) of each donor, a questionnaire
was provided. Approximately 20 ml of venous blood
was drawn from each donor. Also, approximately 20 ul
of capillary blood was obtained for the QIAcard FTA
spots (QIAGEN Inc. Ontario, Canada) from each donor
and were stored in pouches at room temperature after
drying.
Peripheral blood mononuclear cells (PBMC) and plasma
isolation
Immediately after blood draw from each donor, PBMCs
were isolated and purified using Ficoll-Hypaque gradient
centrifugation followed by cryopreservation in liquid
nitrogen using 40% Roswell Park Memorial Institute
(RPMI) medium, endotoxin free 50% fetal bovine serum
and 10% dimethyl sulfoxide (DMSO). Plasma was stored
in appropriate tubes (BD Biosciences, Franklin Lakes,
and NJ) at -80°C. More descriptive methodology is pro-
vided in Additional file 1.
IFNγ-ELISPOT assay
Enzyme-linked immunospot assay kits (human IFN-γ
ELISPOTPRO kits from Mabtech, Nacka Strand, Sweden)
Table 2 Predicted DRB1 alleles and other DRB haplotypes as potential MHC II molecules to CD4+ HA T cell epitopes
(Continued)




HA2 518-532 - DRB1*0101,DRB1*0701, - DRB3*0201,DRB3*0301
DRB1*1001,DRB1*1201 DRB5*0202




NetMHCIIPan tool was used to predict binding affinity of each epitope with DRB1 alleles and other alleles of DR haplotypes (binding affinity: <50 nM (strong) and
>50 nM to <500 nM (weak)). Bold faced epitopes were used in in vitro assays.
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were used to determine the frequency of epitope-specific
IFN-γ secreting T cells in PBMCs from donors. ELISPOT
assays were set up in duplicates. Each SFU corresponds to
one IFNγ-secreting T cell. Data are presented as the mean
SFU per 2 × 105 PBMCs. The negative control was PBMCs
in medium without epitope stimulation and was used to
assess the spontaneous secretion of IFNγ. The positive
control was polyclonal activator anti-CD3 monoclonal
antibody, which helps in determining T cell numbers
and viability and functionality of the immunoassay. To
increase the reliability of T cellular responses, each syn-
thetic epitope was incubated overnight in ELISPOT
plates (without the cells) to detect any non-specific re-
actions [13]. More descriptive methodology is provided
in Additional file 2.
IgG Enzyme-linked immunosorbent assay (IgG ELISA)
Indirect enzyme-linked immunosorbent assay was devel-
oped to quantify specific IgG antibodies to the seasonal
H1N1 and the A (H1N1)pdm09 in the donor plasma
samples. Hemagglutinin of seasonal H1N1 (2008–2009
vaccine strain, A/Brisbane/59/2007) and A (H1N1)pdm09
(A/California/4/2009) were used as antigens in the ELISA
assay (Sino Biological Inc., China). Absorbance at 405 nm
was measured immediately with an ELISA microplate
reader. Absorbance values correspond to the binding
strength of IgG to influenza HA antigens. Assay perform-
ance was validated with the human IgG standard in the
well, considered as positive control. The negative control
was PBS without antigen in the well. The IgG concentra-
tion of the samples was determined using a standard
curve based on the human IgG standard. Absorbance
values two times higher than the absorbance of the nega-
tive control were considered to be positive. More descrip-
tive methodology is provided in Additional file 3.
HLA-DRB1 typing
Low resolution PCR kits with sequence specific primers
for HLA-DR with Taq (Olerup, Stockholm, Sweden)
were used to determine the DRB1 alleles of each donor.
Table 3 Information on donors
Donor ID (age/
gender)







Alleles of DRB1 Alleles of DR
haplotypes
(DRB3, 4 and 5)
D1 (22/M) no no not sure yes no DRB1*13, DRB3*52
DRB1*14
D2 (22/M) no no yes yes no DRB1*04, DRB4*53,
DRB1*15 DRB5*51
D3 (23/F) no no Infection (11/2006) yes no DRB1*04, DRB4*53,
DRB1*15 DRB5*51
D4 (25/M) no no yes yes no DRB1*07 DRB3*52
D5 (23/M) no no yes yes no DRB1*03 DRB3*52
D6 (27/M) no no yes yes no DRB1*04, DRB3*52,
DRB1*17 DRB4*53
D7 (30/F) no yes Infection (06/2009) yes yes DRB1*08, DRB5*51
DRB1*15
D8 (34/M) no yes No yes yes DRB1*07 DRB4*53
D9 (51/F) no no Infection (07/2010) yes no DRB1*07, DRB3*52,
DRB1*17 DRB4*53
D10 (53/M) no no no yes no DRB1*07, DRB4*53
DRB1*13
D11(53/F) no no yes yes no DRB1*07, DRB3*52,
DRB1*17 DRB4*53
D12 (60/F) yes yes yes yes yes DRB1*03 DRB4*52
D13 (66/F) yes yes yes yes yes DRB1*15 DRB4*53,
DRB5*51
D14 (66/M) yes yes yes yes yes DRB1*04 DRB3*52,
DRB4*53
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Olerup specific interpretation and specificity tables were
used for this purpose.
Statistical analysis
Unpaired t-test (two-tailed p-value) was applied to com-
pare the response among groups using Graphpad Prism
version 5.0.
Results
Donors’ flu exposure history and their HLA types
The donors were divided into two cohorts based on
their age: D1 to D8 (age range 22 – 34 years, median 24)
and D9 to D14 (age range 51 – 66 years, median 56.5).
Table 3 presents the results of IgG ELISA (used to iden-
tify the donors’ flu exposure) and DRB1 alleles of donors
based on HLA-typing. IgG ELISA results revealed that
all 14 donors showed the presence of IgG antibodies
specific to seasonal H1N1-HA (A/Brisbane/59/2007).
However, only five donors had A (H1N1)pdm09 (A/
California/04/2009) specific IgG antibodies, and these
had all been immunized with the 2009 flu vaccine. Anti-
body responses to seasonal H1N1 virus antigen were
expected as seasonal H1N1 has been a co-circulating
seasonal strain for the past 33 years and was widely dis-
seminated in the population through natural infections
and annual seasonal vaccinations. IgG ELISA data on
donor's flu exposure history corroborates previous sero-
prevalence studies showing the absence of detectable
antibodies [2].
CD4+ T-cell memory responses to conserved epitopes
To identify the prevalence of any pre-existing CD4+ T
cell immunity we used the direct IFN-γ ELISPOT assay.
When PBMCs (2 × 105) of each healthy donor were in-
cubated over night with each of the synthetic epitopes in
IFN-γ ELISPOT plates, we observed epitope-specific
CD4+ T cell responses. We considered that the CD4+ T
cell response to each of the conserved epitopes is a recall
CD4+ T cell response. IFN-γ secretions from overnight
IFN-γ-assays ensures that the responses are from in vivo
sensitized CD4+ T cells to these epitopes via natural in-
fection and/or vaccinations, i.e. memory CD4+ T cells
rather than by naïve CD4+ T cells expanded in vitro in
response to the in vitro presented epitopes.
Thirteen out of 14 healthy donors generated IFN-γ
CD4+ T cell memory responses to the predicted CD4+
T cell epitopes (Table 4). Of these donors, donor D10
responded to 12/14 epitopes. Donors D1 and D13
responded to only one epitope (518–532). D8 showed
very low response to two epitopes 510–524 and 511–
525 just above the cut-off (10 and 11 SFU respectively).
The IFN-γ producing T cell variation ranged from 10 ±
1.9 SFU to 89 ± 2.3 SFU per 2 × 105 PBMCs among all
donors that responded. The CD4+ T cellular memory
responses of highest magnitude were observed for HA2
epitopes, 511–525, 518–532 and 531–545 with mean
SFU across all responding donors as: 24.1, 31.4 and 27.1
respectively. Details on mean number of responding T
cells for all epitopes are given in Table 5. Only four do-
nors out of fourteen donors (D5, D10, D11, and D14)
responded to HA1 conserved epitopes and the responses
were of a low magnitude (11 ± .22 SFU to 19 ± 2.3 SFU).
Older age-group showed higher magnitude of T-cell re-
sponses to epitopes when compared to younger group.
Immunodominance of CD4+ T cell HA epitopes
Table 4 tabulates the percentage of donors who elic-
ited CD4+ T cellular memory responses to highly
conserved HA epitopes. There are two criteria set for
“immunodominant epitopes” i.e., high frequency of re-
sponse in population (>50%) and a high intensity of
response as compared to all the epitopes tested [14,15]. In
our study, two of the 14 epitopes, 518–532 and 531–545
were identified as “immunodominant” as they elicited
CD4+ T cell response from 85% (12/14) and 71% (10/14)
of donors respectively. In addition, these two epitopes
(518–532 and 531–545) elicited the highest magnitude of
CD4+ responses among all tested epitopes; the number of
IFN-γ producing CD4+ T cells being 89 ± 2.3 and 80 ± 3.3
SFU per 2×105 PBMCs respectively. Epitopes, 511–524
(43%), 510–524 (36%), 377–391 (29%) and 319–333 (29%)
met the criteria to be sub-dominant epitopes based on the
frequency of donors with CD4+ T cell responses i.e. >25%
to <50%.
Influence of MHC class II alleles on CD4+ T cellular
response to conserved HA epitopes
The strongest CD4+ T cellular memory responses were
seen from donor 11 (D11) who has the DRB1*07 and
DRB1*17 alleles (Table 4). D11 showed CD4+ T cell re-
sponse to epitopes 315–329, 319–333, 421–435, 426–
440, 510–524, 511–525, 518–532 and 531–545. D4, is
identical to D11 with regards to DRB1*07. The strongest
responses of D4 were to epitopes 518–532 and 531–545
but no response was seen to the other epitopes to which
D11 responded. D8 who also has the DRB1*07 allele
responded to epitopes 510–524 and 511–525 (albeit
weakly).
On the other hand, D10 who also has DRB1*07 but in
addition, DRB1*13, showed a positive response to many
epitopes in common with D11 along with unique re-
sponses to some epitopes (Table 4). Overlap in their
CD4+ T cell responses was seen for eight out of 11 epi-
topes for D10 and D11. Four epitopes were unique to
D10 (who expresses DRB1*13 along with DRB1*07).
Next we examined responses from donors expressing
the DRB1*04 allele. D14 who expresses the DRB1*04 al-
lele responded to epitopes 19–33, 315–329, 319–333,
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CD4+ epitopes on HA protein
HA1 (1–329 a.a) HA2 (330–561 a.a)
19-33 99-113 104-119 315-329 319-333 377-391 413-427 421-435 426-440 510-524 511-525 518-532 531-545
D1 (22/M) DRB1*13 X
DRB1*14
DRB3*52








D4 (25/M) DRB1*07 X X
DRB3*52
D5 (23/M) DRB1*03 X X X X
DRB3*52




D7 (30/F) DRB1*08, X X X X X
DRB1*15
DRB5*51
D8 (34/M) DRB1*07 X X
DRB4*53

























Table 4 T cell response of donors to predicted and conserved T cell epitopes encompassing entire HA protein (Continued)




D12 (60/F) DRB1*03 X X X X
DRB4*52
D13 (66/F) DRB1*15 X
DRB4*53,
DRB5*51
D14 (66/M) DRB1*04 X X X X X X X X
DRB3*52,
DRB4*53



















377–391, 511–525, 518–532 and 531–545. Donors D2
and D3 both have DRB1*04 and DRB1*15 alleles. How-
ever, only D2 responded to epitopes 518–532 and 531–
545. D6 responded to epitopes 518–532 and 531–545
and expressed DRB1*04 and DRB1*17 alleles. D7 who
expressed DRB1*08, DRB1*15 responded to epitopes of
377–391, 510–524, 511–525, 518–532, and 531–545.
D12 who expressed DRB1*03 allele responded to epi-
topes 510–524, 511–525, 518–532, and 531–545. In
contrast to other donors, D13 was responsive only to
the epitope 518–532. We recognized that two HA2 epi-
topes 518–532 and 531–545 exhibited high promiscuity
since they generated response in donors irrespective of
their MHC backgrounds. The presenting MHC II alleles
listed in the descending order of their promiscuity with
epitopes, are DRB1*07, DRB1*04, DRB1*15 > DRB1*03,
DRB1*17 > DRB1*13, DRB1*14, and DRB1*08. To
summarize, there are instances with donors with same
MHC allele background however responding to different
epitopes and donors with different MHC alleles present
same epitopes (Table 6).
Discussion
Various immuno-informatics studies revealed high degree
of T cell-specific epitope conservancy between seasonal
H1N1 and A(H1N1)pdm09 [5,6,12]. Invitro and invivo T
cellular functional studies assumed that common and
shared epiope-specific T-cell responses are involved in the
attenuation of disease severity of A (H1N1)pdm09 infec-
tion [6,14,15]. In the current study, we have conducted T
cellular functional assays and HLA-typing (MHC II-DRB1)
experiments to identify the immunodominant epitopes of
conserved HA CD4+ T cell epitopes between seasonal
H1N1 and A (H1N1)pdm09.
The over-night T cell functional assays revealed that
the CD4+ T cellular memory responses could readily be
generated to highly conserved HA epitopes from major-
ity of the donors (93%, 13/14). However, we found vari-
ability in reactivity to HA CD4+ T cell epitopes among
donors, which could be correlated to factors such as age,
previous exposure history to similar flu viral strains,
genetics i.e. MHC class II allele promiscuity, and the
binding affinity between MHC and its epitope [14,15].
Older donors showed significantly higher magnitude and
diversified CD4+ T cellular responses when compared to
young (mean SFU across responding donors 136.5 vs.
41.6, unpaired t-test two-tailed p-value = 0.0060). It is
very likely that older adults have larger and more varied
repertoire of CD4+ T memory cells due to repeated sea-
sonal H1N1 exposures. We also observed the highest im-
munogenic (CD4+) responses from donors who expressed
DRB1*07, DRB1*04, DRB1*15 alleles. Of particularly
DRB1*07 was shown to present and elicit CD4+ T cell re-
sponses for 86% (12/14) of epitopes tested.
From our in vitro analysis, we have identified two
immunodominant epitopes (518–532 and 531–545)
from the stalk region of HA protein. Epitope, 531–545,
GAISFWMCSNGSLQC is a unique CD4+ T cell epitope
that has not identified previously as being immunogenic.
The immunodominance of these two epitopes is likely
due to their localization in a highly conserved stalk
(HA2) region of HA, and their high promiscuity with
DRB1 alleles. Extensive promiscuity of epitopes to differ-
ent MHC alleles increases their likelihood of being
presented by majority of population and more likely to
be recognized by a broad CD4+ T cell repertoire. We
also observed that same alleles often present very differ-
ent epitopes. This represents that some MHC alleles can
exhibit less restrictive peptide binding and this type of
phenomena have been observed before [16]. Despite the
presence of a similar MHC background, the availability
of T cell repertoire that recognizes a particular epitopes
determines the response to a given epitope.
Interestingly, immunodominance does not correlate
with the binding affinities of peptide- DRB1*07. Similar
poor correlation results were also documented from
other studies on CD4+ T cell responses to epitopes of
influenza A viruses [17] and other antigens [18-20]. This
poor correlation can possibly be influenced by the anti-
gen abundance and the T cell repertoire. With relevance
to available T cell repertoire on immunodominance, pre-
vious studies have clearly shown that epitope hierarchy
from subdominant to immunodominant could be altered
by pre-immunization with specific epitopes and thereby
increase the frequency of T cells [21,22]. As a result of
repeated exposures to similar Influenza A viruses, T cell
Table 5 Mean number of responding T cells across









19-33 11.5 1 11.5
99-113 0.0 0 0.0
104-119 25.5 2 12.8
315-329 45.5 3 15.2
319-333 38.0 3 12.7
377-391 66.0 4 16.5
413-427 25.5 2 12.8
421-435 58.0 3 19.3
426-440 33.0 3 11.0
510-524 73.5 5 14.7
511-525 144.5 6 24.1
518-532 376.5 12 31.4
531-545 243.5 9 27.1
* Only positive responding T cells (≥ 10) were considered.
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repertoire can be considerably generated to the highly
conserved regions as shown in our study. A recent study
by Wilkinson et al. [23], has shown evidence of pre-
existing influenza-specific CD4+ T cell response to in-
ternal proteins, with cytotoxic activity in reducing viral
shedding and mitigating illness in human volunteers.
The current study provides compelling evidence of epi-
tope specific CD4+ T cellular memory albeit with some
experimental limitations. Based on extensive studies on
optimal size of epitope (15 a.a. length) for CD4+ T cells
we have assumed that the observed T cellular memory re-
sponses are from CD4+ T cells [24]. Additional evidence
for our assumption comes from experimental reports
showing CD4+ T cellular responses to conserved regions
of influenza A virus proteins with memory markers [6,14].
However, we cannot rule out the possibility of low level
Table 6 Information on percentage of donors, and their T cell response and DRB MHC type of donors responding to
predicted and conserved T cell epitopes
HA epitope
and position












STVASSLVLLVSLGA 85 (12/14) 376.5 31.4 DRB1*03, DRB1*04, DRB3*52,
(518–532) DRB1*07, DRB1*08, DRB4*53,
DRB1*13, DRB1*14, DRB5*51
DRB1*15, DRB1*17
GAISFWMCSNGSLQC 71 (9/14) 243.5 27.1 DRB1*03, DRB1*04, DRB3*52,
(531–545) DRB1*07, DRB1*08, DRB4*53,
DRB1*13, DRB1*15, DRB5*51
DRB1*17
YQILAIYSTVASSLV 43 (6/14) 144.5 24.1 DRB1*04, DRB1*07, DRB3*52,
(511–525) DRB1*08, DRB1*13, DRB4*53,
DRB1*15, DRB1*17 DRB5*51
IYQILAIYSTVASSL 36 (5/14) 73.5 14.7 DRB1*07, DRB1*08, DRB3*52,
(510–524) DRB1*13, DRB1*15, DRB4*53,
DRB1*17 DRB5*51
NKVNSVIEKMNTQFT 29 (4/14) 66.0 16.5 DRB1*04, DRB1*07, DRB3*52,
(377–391) DRB1*08, DRB1*13, DRB4*53,
DRB1*15, DRB1*17 DRB5*51
RNIPSIQSRGLFGAI 29 (4/14) 38.0 12.7 DRB1*03, DRB1*04, DRB3*52,
(319–333) DRB1*07, DRB1*13, DRB4*53
DRB1*17
LVLLENERTLDYHDS 21 (3/14) 33.0 11.0 DRB1*07,DRB1*13, DRB3*52,
(426–440) DRB1*17 DRB4*53
YNAELLVLLENERTL 21 (3/14) 58.0 19.3 DRB1*07,DRB1*13, DRB3*52,
(421–435) DRB1*17 DRB4*53
ATGLRNIPSIQSRGL 21 (3/14) 45.5 15.2 DRB1*04, DRB1*07, DRB3*52,
(315–329) DRB1*13, DRB1*17 DRB4*53
DGFLDIWTYNAELLV 14 (2/14) 25.5 12.8 DRB1*03, DRB1*07, DRB3*52,
(413–427) DRB1*13, DRB4*53
QLSSVSSFERFEIFP 14 (2/14) 25.5 12.8 DRB1*04, DRB1*07, DRB3*52,
(104–119) DRB1*13 DRB4*53
VLEKNVTVTHSVNLL 7 (1/14) 11.5 11.5 DRB1*04 DRB3*52,
(19–33) DRB4*53
EELREQLSSVSSFER No response - - - -
(99–113)
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responses from CD8+ T cells to these conserved epitopes.
We also acknowledge that serology by ELISA is not an
ideal way to determine the exposure to flu; the ideal way
would have been to have laboratory confirmed influenza
infection. Further the immunogenic conserved HA epi-
topes identified in the current study have to be validated
on a larger scale to characterize and reconfirm the epitope
immunodominance.
Conclusion
Influenza A viruses belongs to a group of the best stud-
ied viruses, yet they pose a challenge to the human
population in the form of epidemics and pandemics.
One of the drawbacks of current available seasonal influ-
enza trivalent vaccines is that they can elicit potent neu-
tralizing antibody responses against vaccine strains and
closely related antigenic viral strains but not against
antibody-escape variants like novel or pandemic strains.
This limited efficacy of vaccines necessitates annual
reformulation of seasonal vaccines. The greatest threat,
however, is during pandemics when most of the popula-
tion is naïve and thus the pandemic could lead to con-
siderable morbidity and mortality. As shown in our
study, there could be considerable role of pre-existing T
cellular immunity in modulating the disease severity of
pandemic strains even in the absence of pre-existing neu-
tralizing antibodies. Our study also supports the need to
develop vaccines with conserved CD4+ T cell epitopes to
increase the efficacy of vaccines. One of the challenges of
CD4+ T cell epitope based vaccines is MHC class II re-
striction and polymorphism in humans. However, our
study has shown that by large scale bioinformatics analysis
it is possible to identify CD4+ T cell epitopes that promis-
cuously bind to several MHC class II alleles thus have po-
tential for maximal population coverage.
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